US Stock Insider Trading | Kiora Pharmaceuticals disclosed two insider trading transactions on March 6

robot
Abstract generation in progress

On March 6, 2026, Kiora Pharmaceuticals (KPRX) disclosed two insider trading transactions. Executive Daniels Eric Joseph sold 238 shares on March 3, 2026.

【Recent Insider Trades】

Disclosure Date Position Name Trade Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 6, 2026 Director Strem Brian M. March 3, 2026 Sell 238 2.02 480.76
March 6, 2026 Executive Daniels Eric Joseph March 3, 2026 Sell 238 2.02 480.76
September 12, 2024 Director Stengone Carmine N. September 11, 2024 Buy 1250 3.68 4,600.00
September 11, 2024 Director Shapiro Aron September 10, 2024 Buy 3000 3.60 11,000
August 20, 2024 Director Walters-Hoffert Lisa August 19, 2024 Buy 1250 3.86 4,825.00
August 19, 2024 Director TYLE PRAVEEN August 19, 2024 Buy 5000 3.96 19.8k
August 15, 2024 Executive Tosca Melissa August 14, 2024 Buy 2000 3.21 6,420.00
June 14, 2024 Executive Tosca Melissa June 14, 2024 Buy 100 5.25 525.00
June 14, 2024 Executive Daniels Eric Joseph June 14, 2024 Buy 1431 5.29 7,569.99
June 13, 2024 Director Parsons Erin June 13, 2024 Buy 5260 4.88 25.7k

【Company Profile】

Kiora Pharmaceuticals, Inc. was incorporated in Delaware on December 26, 2004, under the name EyeGate Pharmaceuticals, Inc., and changed its name to Kiora Pharmaceuticals, Inc. on November 8, 2021. The company is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies and drug delivery systems for eye diseases.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin